New Key Statistics Module, Z-Score and F-Score
NAS:YMAB Key Ratios
| Market Cap $ M | 536.25 |
| Enterprise Value $ M | 469.58 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 5.48 |
| Price/Sales | 6.41 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 84.00 |
| EPS (TTM) $ | -0.49 |
| Beneish M-Score | -2.27 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 15.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -18.72 |
| EV-to-EBITDA | -19.27 |
| PEG | -- |
| Shares Outstanding M | 43.88 |
| Net Margin (%) | -25.64 |
| Operating Margin % | -29.68 |
| Pre-tax Margin (%) | -24.79 |
| Quick Ratio | 5.67 |
| Current Ratio | 6.15 |
| ROA % (ttm) | -16.67 |
| ROE % (ttm) | -21.12 |
| ROIC % (ttm) | -93.61 |
| Dividend Yield % | -- |
| Altman Z-Score | 9.27 |
YMAB Number of Guru Trades
YMAB Volume of Guru Trades
Gurus Latest Trades with NAS:YMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:YMAB is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Y-mAbs Therapeutics Inc Insider Transactions
No Available Data
News about NAS:YMAB
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers